Phase II Study of Dimethyldiguanide Combined With AI Compared to AI in Postmenopausal HR(+) Metastatic Breast Cancer.
The addition of dimethyldiguanide might increase the efficacy of AI in patients with
metastatic breast cancer after the failure of the first line endocrine therapy.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
progression free survival
Xichun Hu, MD,PhD
China: Ethics Committee